ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, recently announced the presentation of the design for its second phase III trial, COMPOSE (NCT04919226) at the 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference held in a hybrid format in Barcelona during March 10-11, 2022. The study is designed to evaluate the efficacy and safety of ITM’s lead radiopharmaceutical candidate, ITM-11 (n.c.a. 177Lu-edotreotide), in comparison withthe best standard of care for patients with well-differentiated high grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (G2+G3 SSTR+ GEP-NETs). ITM-11 is a Targeted Radionuclide Therapy consisting of the no-carrier-added lutetium-177 (n.c.a. 177Lu) combined with the somatostatin analogue edotreotide.

To read more please visit:

ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of Neuroendocrine Tumors at Annual ENETS Conference 2022

Source: itm